Utilization of Hepatocellular Carcinoma Surveillance Programs in Patients With Cirrhosis: A Systematic Review and Meta-Analysis.
Journal
Journal of clinical gastroenterology
ISSN: 1539-2031
Titre abrégé: J Clin Gastroenterol
Pays: United States
ID NLM: 7910017
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
08
06
2021
accepted:
06
11
2021
pubmed:
10
1
2022
medline:
7
1
2023
entrez:
9
1
2022
Statut:
epublish
Résumé
Patients with cirrhosis are advised to undergo hepatocellular carcinoma (HCC) surveillance every 6 months. Routine surveillance is associated with early tumor detection and improved survival. However, surveillance is underutilized. We aimed to characterize the uptake of HCC surveillance in cirrhotic patients following the implementation of interventional programs. We performed a comprehensive literature search of major databases (from inception to October 2020). Surveillance was defined as having an abdominal sonogram every 6 months. Nine studies were included for meta-analysis which involved 4550 patients. The etiology of liver cirrhosis was largely due to hepatitis C or B (n=2023), followed by alcohol (n=857), and nonalcoholic steatohepatitis (n=432). Patients enrolled in surveillance programs were 6 times more likely to undergo abdominal sonography when compared with standard of care (odds ratio=6.00; 95% confidence interval: 3.35-10.77). On subgroup analysis, clinical reminders were associated with a 4 times higher rate of HCC surveillance compared with standard of care (odds ratio=3.80; 95% confidence interval: 2.25-6.39). Interventional programs significantly improve the rate of HCC surveillance. This is clinically impactful and should be considered as a means for improving surveillance rates.
Identifiants
pubmed: 34999648
doi: 10.1097/MCG.0000000000001668
pii: 00004836-202302000-00013
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-203Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Balogh J, Victor D III, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41.
Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–309.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.
Singal AG, Mittal S, Yerokun OA, et al. Hepatocellular carcinoma surveillance associated with early tumor detection and improved survival among patients with cirrhosis in the US. Am J Med. 2017;130:1099–1106.
Prasad V, Lenzer J, Newman DH. Why cancer surveillance has never been shown to “save lives”—and what we can do about it. BMJ. 2016;352:h6080.
Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72:250–261.
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of surveillance for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624.
van Meer S, de Man RA, Coenraad MJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in The Netherlands. J Hepatol. 2015;63:1156–1163.
Wu CY, Hsu YC, Ho HJ, et al. Association between ultrasonography surveillance and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65:693–701.
Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;65:1148–1154.
Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma surveillance is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17:976.e4–987.e4.
Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014.
Harris PS, Hansen RM, Gray ME, et al. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25:1550–1559.
Amarapurkar D, Han KH, Chan HL, et al. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol. 2009;24:955–961.
Aberra FB, Essenmacher M, Fisher N, et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157–1160.
Aby ES, Winters AC, Lin J, et al. A telephone and mail outreach program successfully increases uptake of hepatocellular carcinoma surveillance. Hepatol Commun. 2020;4:825–833.
Beste LA, Ioannou GN, Yang Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care–oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13:172–179.
Bui HT, Rangchi A, Tran DK, et al. Implementing a local hepatoma surveillance program in patients with cirrhosis secondary to hepatitis C—real world experience in a community based practice. Gastroenterology. 2017;152:S1191–S1192.
Bunnag K, Kongsompong A, Jeamwijitkul W, et al. Quality improvement campaign lead to higher surveillance rate for hepatocellular carcinoma in primary care clinic. Gastroenterology. 2020;158:S-1353.
Farrell C, Halpen A, Cross TJ, et al. Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK. Clin Radiol. 2017;72:338.e11–338.e17.
Kennedy NA, Rodgers A, Altus R, et al. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J. 2013;43:772–777.
Nazareth S, Leembruggen N, Tuma R, et al. Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis. Int J Nurs Pract. 2016;22:3–11.
Singal AG, Tiro JA, Murphy CC, et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial. Hepatology. 2019;69:121–130.
Simmons OL, Feng Y, Parikh ND, et al. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2019;17:766–773.
Singal AG, Tiro JA, Marrero JA, et al. Mailed outreach program increases ultrasound surveillance of patients with cirrhosis for hepatocellular carcinoma. Gastroenterology. 2017;152:608.e4–615.e4.
Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer surveillance among ethnically diverse, low-income patients: a randomized controlled trial. Arch Intern Med. 2011;171:906–912.
Natale-Pereira A, Enard KR, Nevarez L, et al. The role of patient navigators in eliminating health disparities. Cancer. 2011;117:3541–3550.
Lok AS, Seeff LB, Morgan TR, et al. HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148.
Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978.
Ronot M, Pommier R, Dioguardi Burgio M, et al. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol. 2018;91:20170436.
McGowan CE, Edwards TP, Luong MU, et al. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol. 2015;13:799–804.
Deng LX, Mehta N. Does hepatocellular carcinoma surveillance increase survival in at-risk populations? Patient selection, biomarkers, and barriers. Dig Dis Sci. 2020;65:3456–3462.
Robinson A, Tavakoli H, Cheung R, et al. Low rates of retention into hepatocellular carcinoma (HCC) surveillance program after initial HCC surveillance. J Clin Gastroenterol. 2019;53:65–70.
Goldberg DS, Taddei TH, Serper M, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2017;65:864–874.
Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65:875–884.
Goebel M, Singal AG, Nodora J, et al. How can we boost colorectal and hepatocellular cancer surveillance among underserved populations? Curr Gastroenterol Rep. 2015;17:22.
Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9:222–231.
Jerant A, Kravitz RL, Sohler N, et al. Sociopsychological tailoring to address colorectal cancer surveillance disparities: a randomized controlled trial. Ann Fam Med. 2014;12:204–214.
Joseph DA, King JB, Dowling NF, et al. Vital Signs: colorectal cancer surveillance test use—United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69:253–259.
Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019;157:54–64.
Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC surveillance and surveillance. J Hepatocell Carcinoma. 2019;6:131–141.
Moher D, Shamseer L, Clarke M, et al. PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
Schünemann HJ, Cuello C, Akl EA, et al. GRADE Working Group. GRADE Guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105–114.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–680.
Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137–159.
Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. 2011;64:1294–1302.
Easterbrook PJ, Gopalan R, Berlin JA, et al. Publication bias in clinical research. Lancet. 1991;337:867–872.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.
Jin ZC, Zhou XH, He J. Statistical methods for dealing with publication bias in meta-analysis. Stat Med. 2015;34:343–360.